Investigation reports correction on Medicare pricing for oncology biosimilars after publication, suggesting improved accuracy.
In the Original Investigation titled “Hospital Adoption and Pricing for Oncology Biosimilars”1 published online March 11, 2026, how Medicare marks up acquisition of oncology biosimilars compared with biologics was adjusted in the article’s Discussion section. This was corrected online.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: